Table 3.
Clinical outcomes during the study periods.
| baseline | 4 weeks | 8 weeks | p-value‡ | ||
|---|---|---|---|---|---|
| LANSS | Opioid-only | 15.9 ± 2.0 | 13.1 ± 4.1 | 10.7 ± 1.4 | <0.001 |
| Pregabalin add-on | 16.4 ± 3.4 | 10.2 ± 2.4 | 6.9 ± 2.4 | <0.001 | |
| Treatment effect* | — | −3.9 ± 1.3 | −5.8 ± 1.5 | ||
| (p-value†) | — | 0.005 | 0.003 | ||
| VAS-N | Opioid-only | 7.9 ± 2.2 | 5.1 ± 1.6 | 3.3 ± 1.2 | <0.001 |
| Pregabalin add-on | 8.7 ± 1.8 | 4.0 ± 1.0 | 1.9 ± 0.5 | <0.001 | |
| Treatment effect* | — | −2.3 ± 0.6 | −2.9 ± 0.8 | ||
| (p-value†) | — | 0.001 | 0.001 | ||
| VAS-A | Opioid-only | 8.1 ± 1.9 | 5.4 ± 1.5 | 3.6 ± 1.3 | <0.001 |
| Pregabalin add-on | 8.2 ± 1.8 | 4.0 ± 1.3 | 2.2 ± 1.2 | <0.001 | |
| Treatment effect* | — | −1.2 ± 0.5 | −1.5 ± 1.0 | ||
| (p-value†) | — | 0.035 | 0.125 | ||
| NDI | Opioid-only | 20.9 ± 8.9 | 16.8 ± 6.8 | 13.5 ± 3.8 | 0.107 |
| Pregabalin add-on | 21.8 ± 8.1 | 16.3 ± 6.7 | 14.0 ± 5.2 | 0.112 | |
| Treatment effect* | — | 0.6 ± 3.3 | 0.6 ± 1.7 | ||
| (p-value†) | — | 0.847 | 0.706 | ||
| EQ-5D | Opioid-only | 0.57 ± 0.19 | 0.68 ± 0.08 | 0.76 ± 0.08 | 0.150 |
| Pregabalin add-on | 0.62 ± 0.19 | 0.71 ± 0.12 | 0.77 ± 0.11 | 0.117 | |
| Treatment effect* | — | 0.02 ± 0.05 | 0.03 ± 0.02 | ||
| (p-value†) | — | 0.645 | 0.138 |
Abbreviations: LANSS, Leeds assessment of neuropathic symptoms and signs; VAS-N, visual analogue scale for neck pain; VAS-A, visual analogue scale for arm pain; NDI, neck disability index; EQ-5D, EuroQol-5Dimension.
*linear mixed-effects model; †between-group difference; ‡time difference.
The values represent the means ± the standard deviations. Boldface type indicates statistical significance.